Nxera Pharma Co. Ltd. (4565) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Nxera Pharma Co. Ltd. (4565:JPX), powered by AI.

Current Price
¥956
P/E Ratio
-6.9
Market Cap
86.3B
Sector
Healthcare
What is the Nxera Pharma Co. Ltd. stock price forecast?

Nxera Pharma Co. Ltd. is currently trading at ¥956. View real-time AI analysis on Alpha Lenz.

What is Nxera Pharma Co. Ltd. insider trading activity?

View the latest insider trading data for Nxera Pharma Co. Ltd. on Alpha Lenz.

What is Nxera Pharma Co. Ltd.'s P/E ratio?

Nxera Pharma Co. Ltd.'s P/E ratio is -6.9.

Nxera Pharma Co. Ltd.

JPX · 4565
¥956-27(-2.75%)Market closedJPX regular session 09:00–15:00 JST
Ask about Nxera Pharma Co. Ltd.'s future dividend policy...
Alpha Chat Insight

Nxera Pharma Co. Ltd. trades at a P/E of -6.9 (undervalued) with modest ROE of -19.3%. 3Y revenue CAGR of 23.9% highlights clear growth momentum.

Ask for details

Company Overview

Nxera Pharma Co. Ltd. is a biotechnology and pharmaceutical company focused on developing innovative therapies for treating chronic and life-threatening conditions. The company's primary function is to research, develop, and commercialize drugs that address unmet medical needs, making significant strides in the fields of oncology, immunology, and metabolic disorders. With a commitment to scientific research and development, Nxera Pharma Co. Ltd. operates advanced laboratories and leverages cutting-edge technologies to bring breakthrough pharmaceuticals to the market. The company plays a pivotal role in the healthcare sector by introducing new treatment options, aiming to enhance patients' quality of life and contribute to better healthcare outcomes globally. Nxera Pharma Co. Ltd.'s impact extends across various demographics, providing healthcare solutions to both developed and emerging markets through strategic partnerships and collaborations with medical institutions. Its market significance is underscored by its ability to innovate rapidly in response to evolving health challenges, positioning it as a critical player in the global pharmaceutical industry.

CEOMr. Christopher Cargill
SectorHealthcare
IndustryBiotechnology
Employees389

Company Statistics

FY 2025

Profile

¥86,304,586,384Market Cap
¥29,615,000,000Revenue
0.00Shares Out
389Employees

Margins

72.32%Gross
-10.50%EBITDA
-28.57%Operating
-50.48%Pre-Tax
-42.31%Net

Valuation

-6.89P/E
1.41P/B
2.91EV/Sales
-39.66EV/EBITDA
-26.21P/FCF

Growth (CAGR)

23.90%Rev 3Yr
27.35%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-8.75%ROA
-19.35%ROE
-5.22%ROIC

Financial Health

¥20,365,000,000Cash & Cash Equivalents
¥53,425,000,000Net Debt
120.97%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Nxera Pharma Co. Ltd. (ticker: 4565) is a company listed on JPX in the Healthcare sector (Biotechnology). It has approximately 389 employees. Market cap is $86.3B.

The current price is 956 with a P/E ratio of -6.89x and P/B of 1.41x.

ROE is -19.35% and operating margin is -28.57%. Annual revenue is $29.6B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Nxera Pharma Co. Ltd. (4565) Stock Forecast 2026 ¥956 — Price, Financials & Analyst Targets | Alpha Lenz